Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
In recent years, major advances in our understanding of the molecular biology of lung cancer, together with significant improvements in radiotherapy technologies, have revolutionized the treatment of non-small cell lung cancer (NSCLC). This has led to the development of new therapies that target molecular mutations specific to each tumor type, acting on the cell surface antigens or intracellular signaling pathways, or directly affecting cell survival. At the same time, ablative dose radiotherapy can be delivered safely in the context of metastatic disease. In this article, the GOECP/SEOR (Oncological Group for Study of Lung Cancer/Spanish Society of Radiation Oncology) reviews the role of new targeted therapies used in combination with radiotherapy in patients with locally advanced (stage III) NSCLC and in patients with advanced, metastatic (stage IV) NSCLC.
Department of Radiation Oncology, Hospital Universitario Quirón, Calle Diego de Velázquez, 1, 28223, Pozuelo de Alarcón, Madrid, Spain.
F
F
Couñago
Department of Radiation Oncology, Hospital Ruber Internacional, Calle de la Masó, 38, 28034, Madrid, Spain.
A
A
Rodríguez
Department of Radiation Oncology, Hospital Universitario Santiago de Compostela, Travesía de Choupana, s/n, 15706, Santiago de Compostela, Spain.
P
P
Calvo
Department of Radiation Oncology, Hospital Universitario Fundación Jiménez Díaz, Avda. Reyes Católicos, 2, 28040, Madrid, Spain.
J
J
Luna
Department of Radiation Oncology, Hospital Universitario La Ribera, Carretera de Corbera, km 1, 46600, Alzira, Valencia, Spain.
J L
JL
Monroy
Department of Radiation Oncology, Hospital Universitario Santiago de Compostela, Travesía de Choupana, s/n, 15706, Santiago de Compostela, Spain.
B
B
Taboada
Department of Radiation Oncology, Hospital Universitario Puerta del Mar, Av. Ana de Viya, 21, 11009, Cádiz, Spain.
V
V
Díaz
Department of Radiation Oncology, Hospital de la Esperanza, Parc de Salut Mar, Barcelona, Spain. nrodriguez@parcdesalutmar.cat.|IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. nrodriguez@parcdesalutmar.cat.|Universitat Pompeu Fabra, San josé de la Montaña 12, 08024, Barcelona, Spain. nrodriguez@parcdesalutmar.cat.
N
N
Rodríguez de Dios
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D018787:Radiation Oncology
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins
Brain metastases; Non-small-cell lung carcinoma; Oligometastatic non-small cell lung cancer; Radiotherapy; Stereotactic ablative body radiation; Targeted therapy